ABSTRACT. A plasmid pLTR-DT which contained a gene for diphtheria toxin A-chain (DT-A) under the control of the long terminal repeat (LTR) of bovine leukemia virus (BLV) (BLV-LTR) in the multicloning site of pUC-18 was entrapped in cationic liposomes composed of N-(α-trimethylammonioacetyl)-didodecyl-D-glutamate chloride (TMAG), dioleoyl phosphatidylethanolamine (DOPE) and dilauroyl phosphatidylcholine (DLPC) (1:2:2, molar ratio) (TMAG-liposome), and their antitumor effect on BLV-infected tumor cells was examined in vivo. The cationic TMAG-liposome containing pLTR-DT was successively injected into the tumor transplanted to nude mice. The growth of tumor was significantly inhibited by the injection of cationic TMAG-liposome containing pLTR-DT. On the other hand, TMAG-liposome containing pUC18 plasmids showed no such effect. These results suggest that a DT-A expression plasmid under the control of BLV-LTR is highly toxic to the BLV-infected tumor cells, and that the cationic liposomes, such as TMAG-liposome, may be efficient transfection reagent for BLV-infected tumor cells and can be utilized for DT-A gene delivery into BLV-infected tumor cells in vivo. -KEY WORDS: bovine leukemia virus, cationic liposome, gene therapy.
potential usefulness of liposomes as a carrier for gene transfer has attracted considerable interest during the last few years [1, 3, 4, 6, 19, 24] . In particular, positively charged liposomes, which are composed of cationic lipid, are regarded as efficient tool for the gene transfer into the cells, because liposomes containing cationic lipids are more efficient in transfection when compared with the liposomes containing no positively charged lipid [2, 9, 11] , though the transfection efficiency of positively charged liposomes depends on the cells used [11] . More recently, we demonstrated that the number of viable BLV-infected cells was markedly reduced by the treatment with pLTR-DTcontaining cationic liposomes composed of N-(α-trimethylammonioacetyl)-didodecyl-D-glutamate chloride (TMAG), dioleoyl phosphatidylethanolamine (DOPE) and dilauroyl phosphatidylcholine (DLPC) (1:2:2, molar ratio) (TMAG-liposome), and also that the pLTR-DT entrapped by cationic TMAG-liposome was little affected by the treatment with DNase I and serum [10] . These findings prompted us to investigate whether cationic TMAGliposome are efficient at delivering pLTR-DT into BLV-infected cells in vivo.
In this paper, we investigated the delivery of the gene for DT-A in BLV-infected cells in vivo using cationic TMAGliposome and found that positively charged liposomes containing TMAG are suitable for in vivo use, and that the tumor growth was significantly inhibited by the treatment with pLTR-DT-containing cationic TMAG-liposome. This finding indicates that cationic TMAG-liposome entrapping pLTR-DT may have potential usefulness for the gene therapy of EBL.
TMAG was obtained from Sogo Pharmaceutical Co., Ltd., Tokyo, Japan; DOPE from Avanti Polar Lipids, Birmingham, AL; DLPC from Sigma Chemical Co. (Sigma Chemical Co., St. Louis, Mo, U.S.A.). Plasmids pLTR-DT [6] was amplified in Escherichia coli JM 109 and purified Enzootic bovine leukosis (EBL) is a lymphoproliferative disease caused by bovine leukemia virus (BLV) [12] . BLV induces both lymphocytosis, which is characterized by an increased number of B lymphocytes in the peripheral blood [19, 20] , and lymphosarcoma in various lymph nodes in a later stage. One of the most characteristic features of this virus is that the viral genome encodes a specific transcriptional activator called p34 [17, 18, 21] , as is the case with human T-cell leukemia virus (HTLV) type I and II [22] . The transactivation by p34 is assumed to be mandatory for the promoter activity of the long terminal repeat (LTR) of BLV (BLV-LTR), and hence the expression of viral genes. Rosen et al. [18] have shown that p34 present in BLV-infected cells greatly increases gene expression directed by the BLV-LTR. We also previously demonstrated that the promoter activity of BLV-LTR proved to be highly specific to the BLV-infected cells [6] . Therefore, it is thought that the gene for diphtheria toxin A-chain (DT-A) under the control of BLV-LTR (pLTR-DT) is a toxic agent to BLV-infected cells. Actually, syncytium formation induced by BLV-infected cells and the growth of the cells were effectively suppressed by the phosphatidylserine (PS) liposomes containing pLTR-DT [6] .
Liposomes are bilayer vesicles composed of amphiphilic phospholipids. They are non-toxic, biodegradable and poorly immunogenic. Furthermore, the liposomes-entrapped materials are protected from enzymatic attack until they reach the target sites. Recently, liposomes have been used for in vitro gene transfer in the culture cells [2, 5, 6] . However, the greatest potentiality for liposomes-mediated gene transfer seems to lie in its in vivo applications. The by cesium chloride gradient centrifugation method.
Cationic lipsomes entrapping plasmids were prepared from the lipid miture solution containing TMAG (1 µmol), DLPC (2 µmol), and DOPE (2 µmol) as described previously [10] .
The amount of DNA entrapped in liposomes was determined by the method described previously [9] .
Fetal lamb kidney (FLK) cells chronically infected with and producing BLV (FLK/BLV) were used. Cells were maintained in Eagle's minimal essential medium (MEM) (Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) supplemented with 10% fetal calf serum (FCS) and antibiotics. This cell line showed tumorigenicity in athymic nude mice [7] . BALB/c nude mice were inoculated subcutaneously at the back with a single cell suspension of FLK/BLV culture cells (2 × 10 7 cells). When tumor growth was observed (about 2 weeks after injection), mice were divided randomly into 3 groups and treatment with cationic liposomes containing pLTR-DT was started. Each group of animals (4 mice) received 4 injections of cationic liposomes containing pLTR-DT (20 µg), cationic liposomes containing the same dose of pUC18 plasmids, or no treatment at 2-day intervals (days 2, 4, and 6 after the first injection). The mice were sacrificed on day 10 of pLTR-DT-containing cationic liposomes treatment and the effect of the treatment was evaluated based on the tumor size. Tumor size was measured with calipers and the volume was calculated from the equation v (mm 3 )=0.4 × a × b 2 , where a and b are the major and minor diameters, respectively [14] . The significance of differences between the volume of tumors in experimental and control mice was evaluated by means of Student's t-test.
The antitumor effect of cationic TMAG-liposome containing pLTR-DT was studied in vivo by examining its suppressive effect on tumor growth in nude mice inoculated with FLK/BLV cells. The tumors in most of the inoculated nude mice appeared after a similar time interval and the size was similar. When the tumor volume reached about 250 mm 3 , the mice were separated into 3 groups and the mice were given 4 injections of TMAG-liposome containing pLTR-DT or TMAG-liposome containing pUC18 plasmids. After injection, the tumor size was measured every 2 days. Table 1 shows the mean tumor volumes in the 3 groups at day 10. The mean tumor volume of the nontreated control group was 3340.1 ± 1515.4 mm 3 . The values of mean tumor volume in the group treated with pLTR-DTcontaining TMAG-liposome (488.5 ± 75.6 mm 3 , P<0.01) was significantly small as compared with that of the nontreated control group. Furthermore, tumor growth in the group treated with TMAG-liposome containing pLTR-DT was significantly decreased (P<0.02) as compared to that of the pUC18-containing TMAG-liposome-treated group. There was no significant difference in growth inhibition between the nontreated control and pUC18-containing TMAG-liposome-treated groups (Table 1) . Figure 1 shows the tumor growth pattern of animals from each group. Tumor growth in the nontreated control mice was rapid from 3 days after the initial treatment, whereas in the mice treated with cationic TMAG-liposome containing pLTR-DT, the tumor growth was inhibited significantly.
Furthermore, tumors from the pLTR-DT-containing TMAG-liposome-treated and control (nontreated control and pUC18-containing TMAG-liposome-treated mice) groups were examined histologically. Control group showed diffuse proliferation of tumor cells with scant stroma in subcutis. The nuclei of tumor cells were large, round to oval, hyperchromatic nuclei, and contained 2-4 variable-sized prominent nucleoli. The cytoplasm was polyhedral or spindle in shape, with indistinct cytoplasmic borders. Mitotic figures were frequently observed and often atypical. On the other hand, tumors from the pLTR-DT-containing TMAG-liposome-treated mice occasionally contained the degenerated tumor cells with marked vacuolated cytoplasm. There was no significant difference of mitotic activity between control group and the treated group (data not shown). Thus far, gene derivery in vitro and in vivo to the cells with various cationic liposomes has been reported [2, 5, 6, 15, 16, 23, 25] . However, their transfection efficiency is highly dependent on the cell type [11] . More recently, we demonstrated that the suppressive effect of pLTR-DTentrapped TMAG-liposome on the growth of BLV-infected cells in vitro [10] . Thus, it is important to elucidate in vivo antitumor effect of pLTR-DT-containing TMAG-liposome on BLV-infected tumor cells.
In the present study, in vivo experiment demonstrated the therapeutic effect of pLTR-DT-containing TMAG-liposome on FLK/BLV tumor cells. TMAG-liposome treated mice showed significant inhibition of tumor growth when compared to the nontreated control group. No significant difference in tumor growth between the group treated with pUC18-containing TMAG-liposome and nontreated control group was observed. This result would be attributed to the death of FLK/BLV tumor cells by production of diphtheria toxin in such cells, since pLTR-DT works only in BLVinfected cells [6] . Actually, tumor cells in the mice treated with pLTR-DT-containing TMAG-liposome were degenerated with marked vacuolated cytoplasm. Moreover, this also suggests that the cationic TMAG-liposome may be efficient tool for gene transfer into the BLV-infected cells in vivo.
The activation of BLV-LTR is highly dependent on the presence of the BLV p34 trans-activator [17, 18, 21] . Kono et al. [8] have reported that transcription of BLV genes increases in parallel with development of persistent lymphocytosis (PL). In our separate experiment, we also found that cationic TMAG-liposome was able to transfect plasmid DNA into the lymphoid cells (manuscript in preparation). Thus, PL which is thought to be an early stage of EBL is one of the candidates for the delivery of the DT-A gene into BLV-infected cells by the use of cationic liposomes. In order to transfer the gene encapsulated in liposomes to specific cells, furthermore, appropriate cytophilic ligands such as monoclonal antibody are also available; for example, c143 monoclonal antibody, which recognizes tumor-associated antigen (TAA) expressed on EBL tumor cells and peripheral blood lymphocytes (PBL) of cattle with PL [13] , will be useful carrier to deriver the DT-A gene to PBL of cattle with PL. We previously reported that c143 monoclonal antibody-bearing liposomes containing an antitumor drug could lead to a significant inhibition of EBL tumor growth in nude mice [14] . Therefore, c143 monoclonal antibody-conjugated TMAGliposome would be more suitable for in vivo DT-A gene transfer in TAA-positive cells in cattle with PL.
